http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 민용기 (검색결과 248 건)
- 무료
- 기관 내 무료
- 유료
-
-
-
-
-
-
-
-
민용기,이동윤,윤병구,박윤수,문영완,임승재,이영균,최두석 대한골대사학회 2015 대한골대사학회지 Vol.22 No.3
Background: Recently, a Korean fracture-risk assessment tool (FRAX) model has become available, but large prospective cohort studies, which are needed to validate the model, are still lacking, and there has been little effort to evaluate its usefulness. This study evaluated the clinical usefulness of the FRAX model, a FRAX developed by the World Health Organization, in Korea. Methods: In 405 postmenopausal women and 139 men with a proximal femoral fracture, 10-year predicted fracture probabilities calculated by the Korean FRAX model (a country-specific model) were compared with the probabilities calculated with a FRAX model for Japan, which has a similar ethnic background (surrogate model). Results: The 10-year probabilities of major osteoporotic and hip fractures calculated by the Korean model were significantly lower than those calculated by the Japanese model in women and men. The fracture probabilities calculated by each model increased significantly with age in both sexes. In patients aged 70 or older, however, there was a significant difference between the two models. In addition, the Korean model led to lower probabilities for major osteoporotic fracture and hip fracture in women when BMD was excluded from the model than when it was included. Conclusions: The 10-year fracture probabilities calculated with FRAX models might differ between country-specific and surrogate models, and caution is needed when applying a surrogate model to a new population. A large prospective study is warranted to validate the country-specific Korean model in the general population.
-
민용기 대한의사협회 2016 대한의사협회지 Vol.59 No.11
The objectives of this article are to review current pharmacologic approaches for the treatment of osteoporosis in Korea. Calcium and vitamin D supplementation are necessary for osteoporotic patients with inadequate calcium intake and low vitamin D nutritional status, which is a risk factor of osteoporosis. Several pharmacologic therapies are available for treatment of osteoporosis. Antiresorptive agents, bisphosphonates, selective estrogen receptor modulators, denosumab, estrogens, and tibolone are the basis of therapy. Antiresorptive medications reduce the rates of bone remodeling. Several drugs have shown their ability to reduce vertebral and/or nonvertebral fractures in patients with osteoporosis. Bisphosphonates that reduced bone loss and fragility are usually the mainstay of the treatment of osteoporosis. The recently registered denosumab shows similar anti-fracture efficacy by neutralizing receptor activator of nuclear factor-κB ligand, however, marked differences in reversibility can be observed between the two drugs. The anabolic agents, teriparatide, stimulates new bone formation, increases bone density, and reduces fractures. Other treatment options such as hormone replacement therapy, tibolone, raloxifene, and bazedoxifene are also reviewed in this article. Pharmacologic treatments of osteoporosis are associated with adverse effects, but the benefits generally far surpass the risks.
-
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
